3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Renal Insufficiency
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lung Neoplasms
1
Liver Failure
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
Specimen Handling
4
lutetium Lu 177 dotatate
3
gallium Ga 68 dotatate
3
Magnetic Resonance Spectroscopy
3
olaparib
2
cabozantinib
2
belzutifan
2
Temozolomide
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Biopsy
2
6-fluorodopamine
2
3-Iodobenzylguanidine
2
tipifarnib
1
talazoparib
1
spartalizumab
1
pembrolizumab
1
pegfilgrastim
1
lanreotide
1
guadecitabine
1
fluorodopa F 18
1
fludarabine phosphate
1
copper dotatate CU-64
1
atezolizumab
1
Stem Cell Transplantation
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Interleukin-13
1
Granulocyte Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
veliparib
×
1 year
×
Clear all
No trials found.